Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: A preclinical study

Molecular Cancer Therapeutics

Volumn 13, Issue 3, 2014, Pages 714-723

  Kathawala, Rishil J ^a   Sodani, Kamlesh ^a   Chen, Kang ^b,c,d,e   Patel, Atish ^a   Abuznait, Alaa H ^f   Anreddy, Nagaraju ^a   Sun, Yue Li ^a   Kaddoumi, Amal ^f   Ashby Jr , Charles R ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHARANTHINE; CISPLATIN; DOCETAXEL; MASITINIB; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; STEM CELL FACTOR RECEPTOR; VINBLASTINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN HEK293; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SCIENCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PACLITAXEL; THIAZOLES;

EID: 84896299453     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0743     Document Type: Article

References (37)

1. Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 1999;4:408-16. (Pubitemid 29508741)
2. Whelan J. Targeted taxane therapy for cancer. Drug Discov Today 2002;7:90-2. (Pubitemid 34088128)
3. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993;53:747-54. (Pubitemid 23077856)
4. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34. (Pubitemid 43336035)
5. Sodani K, Patel A, Kathawala RJ, Chen ZS. Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer 2012;31:58-72.
6. Malofeeva EV, Domanitskaya N, Gudima M, Hopper-Borge EA. Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res 2012;72:6457-67.
7. Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, et al. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res 2011;71:3649-57.
8. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 2003;63:351-8. (Pubitemid 36158370)
9. Kathawala RJ, Wang YJ, Ashby CR Jr, Chen ZS. Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chin J Cancer. Epub 2013 Oct 9.
10. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 2009;4:e7258.
11. Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009;64:1194-201.
12. D'Allard D, Gay J, Descarpentries C, Frisan E, Adam K, Verdier F, et al. Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS ONE 2013;8:e60961.
13. Le Cesne A, Blay JY, Bui BN, Bouche O, Adenis A, Domont J, et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010;46:1344-51.
14. Campanella NC, de Oliveira AT, Scapulatempo-Neto C, Guimaraes DP, Reis RM. Biomarkers and novel therapeutic targets in gastrointestinal stromal tumors (GISTs). Recent Pat Anticancer Drug Discov 2013;8:288-97.
15. Kim EJ, Zalupski MM. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J Surg Oncol 2011;104:901-6.
16. Italiano A, Bui B. Gastrointestinal stromal tumors: molecular aspects and therapeutic implications. Bull Cancer 2008;95:107-16. (Pubitemid 351262489)
17. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, et al. Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2009;77:993-1001.
18. Shen T, Kuang YH, Ashby CR, Lei Y, Chen A, Zhou Y, et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS ONE 2009;4:e7520.
19. Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2010;79:154-61.
20. Sun YL, Chen JJ, Kumar P, Chen K, Sodani K, Patel A, et al. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS ONE 2013;8:e55576.
21. Deng W, Dai CL, Chen JJ, Kathawala RJ, Sun YL, Chen HF, et al. Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncol Rep 2013;29:2479-85.
22. Shiraishi N, Akiyama S, Nakagawa M, Kobayashi M, Kuwano M. Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res 1987;47:2413-6. (Pubitemid 17099206)
23. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily Gmember 2-mediated drug resistance. Cancer Res 2007;67:11012-20. (Pubitemid 350145931)
24. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999;128:403-11. (Pubitemid 29458600)
25. Yang D, Kathawala RJ, Chufan EE, Patel A, Ambudkar SV, Chen ZS, et al. Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Future Oncol. Epub 2013 Dec 3.
26. Chen K, Xu W, Wilson M, He B, Miller NW, Bengten E, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol 2009;10:889-98.
27. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988;12:345-55.
28. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42. (Pubitemid 17027905)
29. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-14.
30. Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lubbert M, Peschel C, et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009;15:3705-15.
31. Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, et al. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol 2004;56:1061-6. (Pubitemid 39140063)
32. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, et al. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett 2013;328:307-17.
33. Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 2011;79:276-84.
34. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005;4:18.
35. Keizer HG, Joenje H. Increased cytosolic pH in multidrug-resistant human lung tumor cells: effect of verapamil. J Natl Cancer Inst 1989;81:706-9. (Pubitemid 19115762)
36. Vanhoefer U, Cao S, Minderman H, Toth K, Scheper RJ, Slovak ML, et al. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 1996;2:369-77. (Pubitemid 26075640)
37. Humbert M, Casteran N, Letard S, Hanssens K, Iovanna J, Finetti P, et al. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE 2010;5:e9430.